The Impact of PtNPs and CDDP on a Rabbit Hepatocellular Carcinoma Model

Hepatocellular carcinoma (HCC), the most common primary liver cancer, accounts for approximately 90% of all liver cancer cases. Asia and sub-Saharan Africa, where hepatitis B infection is common and many people are infected from birth, are the regions with the highest incidence of HCC cases and the lowest post-treatment survival rates. In order to treat rabbits with HCC, this study evaluated the anticancer activity of platinum nanoparticles (PtNPs) to that of cisplatin (CDDP). Measurement of antioxidant activity against diethylnitrosamine (DEN)-induced oxidative stress in liver tissue was used to assess the effectiveness of PtNP therapy. Malondialdehyde (MDA) level, superoxide dismutase (SOD) activity, and reduced glutathione (GSH) content were all measured. In addition to assessing the liver tissue’s cytochrome c, caspase-3, and serum alpha-fetoprotein (AFP) levels, liver function tests have been also performed. The relative quantification of the genes for tumor protein p53, matrix metallopeptidase 9, and B-cell lymphoma 2 had also been carried out using complete RNA extraction from biopsies of liver tissue. Since it improved the study’s variables to those of typical control animals, the results demonstrated that PtNPs are more effective than CDDP in treating rabbit HCC brought on by DEN. In histological investigations of the DEN group treated with PtNPs, such results were well acknowledged. This suggests, therefore, that PtNPs can act as a promising agent for the treatment of HCC and could therefore interest future investigations.